A Phase 1/2 Trial of ADI-270 in ccRCC
A phase 1/2 trial of ADI-270, Fludarabine, Cyclophosphamide in renal cell carcinoma, run by Adicet Therapeutics, active and no longer recruiting.
Overview
A Phase 1/2 Trial of ADI-270 in ccRCC is a phase 1/2 interventional study registered as NCT06480565 by Adicet Therapeutics, with 60 participants planned, started 2024-12-12 and due to reach its primary completion in 2026-12. Interventions recorded: ADI-270, Fludarabine, Cyclophosphamide. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Shares Fludarabine, Renal cell carcinoma.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.